Inside the Nanyang Biologics SPAC Deal: Valuation, Risks, Close
Nanyang Biologics is a Singapore-based AI-driven drug discovery and biotech company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The setup offers a high-upside AI biotech story, but shareholders should watch valuation, redemptions, and dilution closely.
Nanyang Biologics is a Singapore-based AI-driven drug discovery and biotech company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The setup offers a high-upside AI biotech story, but shareholders should watch valuation, redemptions, and dilution closely.
Deal at a Glance
SPAC partner: RF Acquisition Corp II
SPAC ticker (trades now): RFAI
Expected post-merger ticker: NYB
Implied valuation: $1.5B-$2.2B
Expected close: late Q3 2026
Est. first trading date: late Q3 2026
Deal status: Shareholder vote scheduled
Source filing: SEC 425 (2026-08-20)
Company Overview
Nanyang Biologics Pte. Ltd. is a Singapore-based AI-driven drug discovery and biotechnology company founded in 2021. Its core platform, Vecura, is an agentic AI system for molecular discovery and life science research that the company says combines proprietary AI models, curated natural datasets, and scientific workflows. Nanyang says it has 200+ AI models and access to more than 1.5 million natural compounds sourced from 50,000+ underexplored species.
The company operates across three pillars: drug development for chronic diseases, AI drug discovery, and nutraceuticals. Its drug-development programs are still preclinical/discovery stage, none of its product candidates has been approved for marketing, and no clinical trials have begun. The nutraceutical side is earlier but more commercialized, with CaraViva-Holistic Revival launched in Q3 2025 and additional products planned for 2025 through 2027.
Industry-wise, the proxy frames AI drug discovery as a market where software can compress target identification and lead optimization versus labor-intensive trial-and-error methods. Nanyang positions itself against both in-house pharma AI efforts and standalone AI drug discovery companies, including Recursion Pharmaceuticals (RXRX).
The SPAC Deal
Nanyang Biologics is merging with RF Acquisition Corp II, which trades today under the ticker RFAI. The combined company is expected to list on Nasdaq under the reserved ticker NYB. Based on the shareholder-vote stage reached on August 19, 2026, the most likely first-trading window is shortly after the vote, in late Q3 2026, assuming the transaction cleared and closed on schedule.
On valuation, the clearest primary-source anchor is the board-reviewed third-party valuation range of $1.5 billion to $2.2 billion for Nanyang. The board also said Nanyang initially sought about $2.0 billion, while RFAC was prepared to support $1.5 billion. That makes this a meaningful valuation for a company that is still preclinical on its drug-development pipeline. The filing does not provide a single simple pro forma enterprise value line in the sections reviewed, so the best read is that the deal values Nanyang in that $1.5 billion to $2.2 billion band.
Redemption risk is real. RFAC’s trust account was $119.1 million as of December 31, 2024 and $52.3 million as of December 31, 2025, after approximately $71.6 million was removed from trust in a prior redemption on November 10, 2025. The company also had just $337,383 of cash outside trust and a working capital deficit of $567,649 at year-end 2025. The proxy includes both no-redemption and maximum-redemption cases, which is a clear signal that the deal’s cash outcome could vary materially.
The filing did not disclose a PIPE. It does mention up to $1.5 million of working capital loans that may be convertible into working capital units at $10.00 per unit, but that is not the same as committed PIPE financing. Dilution is also part of the setup: the sponsor’s private placement shares will convert into 388,281 PubCo ordinary shares, and its private placement rights into 19,414 PubCo ordinary shares after the business combination. The proxy also references warrants and rights in the capital structure, but it does not provide a clean one-line total warrant overhang summary in the sections reviewed.
Status-wise, the deal was announced on October 2, 2025, the definitive proxy/prospectus was filed and mailed in late July 2026, and the extraordinary general meeting was held on August 19, 2026. The sources reviewed do not confirm whether the merger has already closed or been terminated after that vote stage.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The SPAC route gives Nanyang a faster path to the public markets than a traditional IPO and lets the company present a long-term growth story around AI-enabled drug discovery, natural compounds, and future product launches. For a business still in preclinical development, the structure can also help it market a forward-looking narrative around platform value rather than only near-term revenue.
The deal also gives Nanyang access to public equity capital and the credibility of a listed currency, while RF Acquisition Corp II brings the merger vehicle, sponsor backing, and the mechanics needed to complete a de-SPAC. That said, the tradeoff is the usual SPAC stack: redemption risk, sponsor dilution, and the possibility that the cash delivered at close is much lower than the trust balance suggests.
Financial Highlights
For the fiscal year ended September 30, 2025, Nanyang reported net income of about $1.3 million, versus a net loss of about $3.6 million in FY2024. The improvement was driven mainly by a one-time NTU MRCA termination gain of $4.709 million and lower R&D spending. The company says that gain was non-recurring and non-cash, so shareholders should not treat it as a repeatable earnings base.
R&D expense fell sharply to $179,376 in FY2025 from $3.093 million in FY2024, largely because the NTU master research collaboration agreement was terminated on December 14, 2024. Cash and cash equivalents were not fully disclosed in the excerpted material provided here, but the SPAC side of the transaction had only $337,383 of cash outside trust at year-end 2025, which underscores how important closing proceeds and redemption levels are to the combined company’s near-term funding picture.
Risk Factors
The biggest de-SPAC risk is redemption. RFAC’s trust was cut from $119.1 million at December 31, 2024 to $52.3 million at December 31, 2025, and a prior redemption removed about $71.6 million from trust. If redemptions are heavy again, the cash that actually reaches the combined company could be far below the headline trust balance, which would pressure the post-close balance sheet and the company’s ability to fund development.
Dilution is another major issue. The sponsor promote, private placement shares, private placement rights, and warrants all sit ahead of public shareholders in the capital stack. On top of that, Nanyang is still early stage: its drug-development programs are preclinical, no product candidate is approved, and no clinical trials have started. That means the valuation is being set against a business with limited clinical validation and a long path to commercialization. Shareholders should also watch for deal-break risk if the vote or closing process does not complete as expected, and for runway risk if the transaction closes with less cash than planned.
Comparable Public Companies
A reasonable peer set includes Recursion Pharmaceuticals (RXRX), Schrodinger (SDGR), and Absci (ABSI). These names are all tied to AI-enabled or computational drug discovery, though each has a different mix of platform revenue, partnerships, and pipeline maturity. In the public market, they tend to trade more on platform credibility, data generation, and pipeline optionality than on near-term earnings.
The comp group has generally been volatile rather than steady, which is typical for early-stage biotech and AI-drug-discovery names. RXRX and ABSI are more development-stage and tend to move on pipeline updates, while SDGR has a broader software-and-discovery model that can sometimes support a different valuation profile. For Nanyang, the key question is whether the market views Vecura as a differentiated platform with real monetization potential or as an early-stage story that still needs clinical proof.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
This is a classic high-variance de-SPAC: an ambitious AI biotech story, a large implied valuation, and a cash outcome that depends heavily on redemptions. The setup favors investors who want exposure to a speculative platform story, but shareholders should watch the trust balance, any final closing disclosure, and the fully diluted share count before assuming the headline valuation translates into real equity value.
Why this matters now is simple: the deal has already reached the vote stage, so the market is moving from story to execution. If the merger closes with manageable redemptions and no surprise financing gaps, NYB could debut as a public AI-biotech name under the NYB ticker. If redemptions are heavy or dilution proves larger than expected, the post-merger stock could start life with a much tighter cash cushion than the headline deal suggests.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.